Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

Summary

This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers. After central biomarker screening, each participant is assigned the best-matched dual-target construct from a predefined target-pair library. The trial is designed to test whether biomarkerguided dual targeting can improve tumor control, reduce antigenescape risk, and preserve safety in solid tumors.

Timeline

Start

2026-03-02

Primary completion

2027-04-14

Completion

2028-03-17

Drugs

Indications